 |
|
|
|
|
Washington Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing WashingtonLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Theraclone Sciences, Inc.
| | | | | Phone: | (206) 805-1600 | | Fax: | (206) 805-1699 | | Year Established: | 2004 | | Employees: | 23 | | Main Contact: | Russ Hawkinson, CFO | | | | Other Contacts: | Kristine Swiderek, Ph.D., CSO
Clifford J. Stocks, CEO
| | | | Company Description | Theraclone Sciences (formerly Spaltudaq) is a biopharmaceutical company committed to the development and commercialization of therapeutic monoclonal antibodies for the treatment of infectious disease and inflammation. Theraclone is a privately-held organization with venture investment from ARCH Venture Partners, Canaan Partners and Healthcare Ventures.
On August 1, 2013 PharmAthene and Theraclone announced an agreement for the merger of the companies in an all-stock transaction. Under terms of the agreement, PharmAthene will issue shares of common stock to Theraclone stockholders such that Theraclone stockholders will own 50% of the combined company. | |
|
|
|
|
|
|
|
